Clinical Biology and Potential Use of Thrombopoietin
The discovery of platelet growth factors raised expectations that an effective method for abrogating thrombocytopenia would soon be available in the clinic. The cytokines initially described were pleiotropic in nature, and stimulation of platelet production was generally modest. However, one of thes...
Saved in:
Main Author: | Russell Basser |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2000-01-01
|
Series: | Canadian Journal of Gastroenterology |
Online Access: | http://dx.doi.org/10.1155/2000/681394 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Icaritin Provokes Serum Thrombopoietin and Downregulates Thrombopoietin/MPL of the Bone Marrow in a Mouse Model of Immune Thrombocytopenia
by: Ke Zhang, et al.
Published: (2018-01-01) -
Letter regarding “Plasma concentration of thrombopoietin in dogs with immune thrombocytopenia”
by: Matthew K. Wun
Published: (2025-01-01) -
Impact of Thrombopoietin Receptor Agonists on Pathophysiology of Pediatric Immune Thrombocytopenia
by: Paschalis Evangelidis, et al.
Published: (2025-01-01) -
Response to letter regarding “Plasma concentration of thrombopoietin in dogs with immune thrombocytopenia”
by: Marjory B. Brooks, et al.
Published: (2025-01-01) -
The Use of Thrombopoietin Receptor Agonists for Correction of Thrombocytopenia prior to Elective Procedures in Chronic Liver Diseases: Review of Current Evidence
by: Kamran Qureshi, et al.
Published: (2016-01-01)